{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:46:54Z","timestamp":1773197214344,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":1467,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.kint.2019.04.027","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T22:55:39Z","timestamp":1557960939000},"page":"1030-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes\u00a0and stage 4 chronic kidney disease"],"prefix":"10.1016","volume":"96","author":[{"given":"Peter","family":"Rossing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey A.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie P.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie","family":"Goldsberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin J.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Packham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo E.","family":"Pergola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Spinowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart M.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.04.027_bib1","doi-asserted-by":"crossref","first-page":"F1589","DOI":"10.1152\/ajprenal.00142.2008","article-title":"Disease-dependent mechanisms of albuminuria","volume":"6","author":"Comper","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.04.027_bib2","first-page":"S1","article-title":"KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"1","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2019.04.027_bib3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0272-6386(99)70442-7","article-title":"Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation","volume":"5","author":"Keane","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.04.027_bib4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. \u201cGruppo Italiano di Studi Epidemiologici in Nefrologia\u201d (GISEN)","volume":"5","author":"Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.027_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/diab.42.5.715","article-title":"Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients","volume":"5","author":"Rossing","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2019.04.027_bib6","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ki.1996.481","article-title":"Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group","volume":"5","author":"Breyer","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.027_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2019.04.027_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2019.04.027_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3317\/jraas.2000.062","article-title":"The losartan renal protection study\u2014rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)","volume":"4","author":"Brenner","year":"2000","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.kint.2019.04.027_bib10","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"6","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.027_bib11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/eurheartj\/ehr017","article-title":"Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials","volume":"12","author":"Holtkamp","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2019.04.027_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"12","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.027_bib13","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"23","author":"Jamerson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.027_bib14","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"9721","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2019.04.027_bib15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"9638","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2019.04.027_bib16","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"23","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.027_bib17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0140-6736(10)60098-0","article-title":"Composite renal endpoints: was ACCOMPLISH accomplished?","volume":"9721","author":"Heerspink","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2019.04.027_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrneph.2009.109","article-title":"Proteinuria: is the ONTARGET renal substudy actually off target?","volume":"8","author":"Ruggenenti","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2019.04.027_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/np100826q","article-title":"New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress","volume":"3","author":"Sporn","year":"2011","journal-title":"J\u00a0Nat Prod"},{"key":"10.1016\/j.kint.2019.04.027_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ki.2012.439","article-title":"Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease","volume":"6","author":"Ruiz","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.027_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"4","author":"Pergola","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.027_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000327599","article-title":"Effect of bardoxolone on kidney function in patients with T2D and stage 3b-4 CKD","volume":"33","author":"Pergola","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2019.04.027_bib23","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"26","author":"de Zeeuw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.027_bib24","doi-asserted-by":"crossref","first-page":"F430","DOI":"10.1152\/ajprenal.00010.2006","article-title":"Model of albumin reabsorption in the proximal tubule","volume":"1","author":"Lazzara","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.04.027_bib25","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1681\/ASN.2012050457","article-title":"Bardoxolone methyl decreases megalin and activates nrf2 in the kidney","volume":"10","author":"Reisman","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.027_bib26","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/ndt\/gft445","article-title":"Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial","volume":"11","author":"Lambers","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.04.027_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI16079","article-title":"Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in\u00a0vitro and in\u00a0vivo","volume":"4","author":"Tang","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2019.04.027_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1172\/JCI118755","article-title":"Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions: evidence for a role for insulin-like growth factor I","volume":"1","author":"Hirschberg","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2019.04.027_bib29","first-page":"1111","article-title":"A\u00a0relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome","volume":"5","author":"Eddy","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2019.04.027_bib30","first-page":"719","article-title":"Interstitial nephritis induced by protein-overload proteinuria","volume":"4","author":"Eddy","year":"1989","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2019.04.027_bib31","first-page":"1179","article-title":"Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway","volume":"5","author":"Morigi","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.027_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000098432","article-title":"Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells","volume":"1","author":"Whaley-Connell","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2019.04.027_bib33","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1046\/j.1523-1755.1998.00905.x","article-title":"Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation","volume":"6","author":"Zoja","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.027_bib34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1681\/ASN.V8101537","article-title":"Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein","volume":"10","author":"Wang","year":"1997","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.027_bib35","series-title":"Targeting Keap1-Nrf2 pathway ameliorates renal inflammation and fibrosis in mice with protein-overload proteinuria","author":"Zoja","year":"2010"},{"key":"10.1016\/j.kint.2019.04.027_bib36","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"21","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2019.04.027_bib37","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"19","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2019.04.027_bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/00498254.2013.852705","article-title":"The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease","volume":"6","author":"Aminzadeh","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1016\/j.kint.2019.04.027_bib39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.redox.2013.10.007","article-title":"The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease","volume":"1","author":"Aminzadeh","year":"2013","journal-title":"Redox Biol"},{"key":"10.1016\/j.kint.2019.04.027_bib40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/ki.2012.393","article-title":"The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells","volume":"5","author":"Ding","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.027_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000486398","article-title":"Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from Bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study","volume":"1","author":"Chin","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2019.04.027_bib42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000346948","article-title":"Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)","volume":"3","author":"de Zeeuw","year":"2013","journal-title":"Am J Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819305034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819305034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:55:03Z","timestamp":1758761703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819305034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0085253819305034"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.04.027","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes\u00a0and stage 4 chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}